Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Depreciation & Amortization (CF): 2022-2025

Historic Depreciation & Amortization (CF) for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $442,000.

  • Stoke Therapeutics' Depreciation & Amortization (CF) fell 18.15% to $442,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 17.00%. This contributed to the annual value of $2.2 million for FY2024, which is 12.00% down from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Depreciation & Amortization (CF) is $442,000, which was down 0.90% from $446,000 recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Depreciation & Amortization (CF) registered a high of $655,000 during Q4 2023, and its lowest value of $247,000 during Q1 2022.
  • For the 3-year period, Stoke Therapeutics' Depreciation & Amortization (CF) averaged around $551,364, with its median value being $549,000 (2024).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 141.70% in 2023, then dropped by 18.61% in 2025.
  • Quarterly analysis of 4 years shows Stoke Therapeutics' Depreciation & Amortization (CF) stood at $609,000 in 2022, then climbed by 7.55% to $655,000 in 2023, then fell by 16.18% to $549,000 in 2024, then fell by 18.15% to $442,000 in 2025.
  • Its last three reported values are $442,000 in Q3 2025, $446,000 for Q2 2025, and $477,000 during Q1 2025.